Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | TK1 | P04183 | 6/20 | 0.60 |
| ▸ | TYMS | P04818 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21163947 | 1.00 | POLB (0.63) | POLBTK1TYMS | |
| SCHEMBL20109714 | 1.00 | POLB (0.63) | POLBTK1TYMS | |
| SCHEMBL3345511 | 1.00 | POLB (0.63) | POLBTK1TYMS | |
| SCHEMBL20115166 | 1.00 | POLB (0.63) | POLBTK1TYMS | |
| SCHEMBL8146361 | 0.91 | POLB (0.63) | POLBTK1TYMS | |
| SCHEMBL8133205 | 0.90 | POLB (0.62) | POLBTK1TYMS | |
| SCHEMBL11876308 | 0.88 | TYMS (0.60) | POLBTK1TYMS | |
| SCHEMBL766555 | 0.88 | TYMS (0.60) | POLBTK1TYMS | |
| SCHEMBL11876295 | 0.88 | TYMS (0.60) | POLBTK1TYMS | |
| SCHEMBL11881949 | 0.88 | TYMS (0.60) | POLBTK1TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10633408-B2 | Nucleoside-lipid compounds with pH-sensitive dialkylorthoester chains and their use for transportation or vectorization of at least one therapeutic agent | Universite de Bordeaux (FR) | 2020-04-28 | — | — | US | disclosed |
| WO-2013014445-A1 | DERIVATIVES OF PHENYL (THIO) UREA DEOXYTHYMIDINE AND USE THEREOF AS ANTIMALARIALS | UNIVERSITY OF DUNDEE (GB) | 2013-01-31 | — | — | WO | disclosed |
| US-20120135092-A1 | INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, THE | 2012-05-31 | — | — | US | disclosed |
| US-20100292135-A1 | INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-11-18 | — | — | US | disclosed |
| EP-1425417-B1 | INTERACTION DETECTION ON SEVERAL PROBE ARRAYS | CLONDIAG CHIP TECH GMBH (DE) | 2007-10-31 | — | — | EP | disclosed |
| US-20060199768-A1 | Inhibitors of RecA activities for control of antibiotic-resistant bacterial pathogens | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2006-09-07 | — | — | US | disclosed |
| EP-1425417-A2 | INTERACTION DETECTION ON SEVERAL PROBE ARRAYS | Clondiag Chip Technologies GmbH (DE) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003018838-A2 | INTERACTION DETECTION ON SEVERAL PROBE ARRAYS | CLONDIAG CHIP TECHNOLOGIES GMBH (DE) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199768-A1 | Inhibitors of RecA activities for control of antibiotic-resistant bacterial pathogens | RECQL, DNA2, WRN | POLB 87/4885TK1 656/4885TYMS 316/4885 |
| US-20100292135-A1 | INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS | RECQL, DNA2, WRN | POLB 87/4885TK1 656/4885TYMS 316/4885 |
| US-10633408-B2 | Nucleoside-lipid compounds with pH-sensitive dialkylorthoester chains and their use for transportation or vectorization of at least one therapeutic agent | SLC29A2, SLC29A1, SAMHD1 | POLB 926/4885TK1 77/4885TYMS 246/4885 |
| US-20120135092-A1 | INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS | RECQL, WRN, ADAR | POLB 252/4885TK1 714/4885TYMS 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.